Hidekatsu Kuroda

1. Introduction Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, and its poor prognosis makes it the third leading cause of cancer-related death [1]. As a systemic therapy for unresectable HCC (u-HCC), cabozantinib (CAB) is considered a second-line treatment option after atezolizumab plus bevacizumab or durvalumab plus tremelimumab [2,3].

AAA aromatic amino acid ALF acute liver failure BBB blood–brain barrier BCAA branched-chain amino acids BEE basal energy expenditure HE hepatic encephalopathy ICH intracranial hypertension JHEP Japan HE prediction REE resting energy expenditure INTRODUCTION The liver is the central organ involved in the metabolism of any nutrient.1 Acute liver failure is a rare disease with a poor prognosis when accompanying HE.2, 3 The rapid deterioration of liver function results in various symptoms that...